The Impact of Genetic Mutational Typing of Endometrial Carcinoma for Adjuvant Oncologic Treatment and Treatment Outcome
Şu kitabın bölümü:
Bilgili,
A.
(ed.)
2023.
Current Researches in Health Sciences-III.
Özet
The adjuvant treatment of endometrial carcinomas took a different turn when ESGO/ESTRO/ESP announced its prognostic risk group guide in 2020. The Cancer Genome Atlas (TCGA) Research Network Classification and the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) algorithm were integrated into clinical practice. Therefore, by combining genomic traits with molecular subtypes, doctors have enhanced patient care and risk stratification for endometrial cancer. Surgery (hysterectomy and bilateral salphingooopherectomy with or without lymph node dissection) is the primary treatment for early-stage, low-grade, low-risk tumors. Vaginal brachytherapy in an adjuvant setting has secured the treatment success for local control. Intermediate-high-risk cancer patients are scheduled for adjuvant chemoradiation and/or vaginal brachytherapy.
Anahtar Kelimeler:
Kaynakça Gösterimi
Lisans
Bu çalışma Creative Commons Attribution 4.0 International License ile lisanslanmıştır.
Yayın Tarihi
DOI
Kategoriler
Telif Hakkı (c) 2023 Ali Bilgili; Fatih Baygutalp- Lale Duysak- Edip Urhan- H. Yeşim Can- Sevil Alkan- Ali Emre Sevik- Buse Keskindağ- Veysel Tosun- Bengü Depboylu- Ege Rıza Karagür- Fatimeh Alghazawi- Bilge Büyükşirin- Büşra Candiri- Amine Nur Arıkan- Sanem Can Çolak- Feride Mehmetoğlu- Ayşe Gülbin Kavak- Merve Gördağ- İ. İlknur Uysal- Aytül Bayraktar- Nastaran Azami- Amirkasra Dehghani- Elif Sibel Aslan- Sajjad Eslamkhah